ClinicalTrials.gg
Not yet recruitingNCT07693127Updated Jul 9, 2026

Red Blood Cell and Platelet Indices for Predicting Outcomes in Acute Exacerbations of COPD

An observational study in Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD) and AECOPD, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Assiut University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 46 studies in Pulmonary Disease, Chronic Obstructive by Assiut University — 23 open to participants now, 24 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Assiut University.

Planned enrollment
30th of 33
50 · median 104
Started
2026
with 7 others
Observational
33 of 46
19 open now
Primary completion
2027-08
later than 18 of 23 live
Registered
43rd of 46
by date

Among the 46 studies in Pulmonary Disease, Chronic Obstructive by Assiut University, this one is the 30th largest by planned enrollment of the 33 observational ones that give a count, is one of 8 that started in 2026, is one of 33 observational ones, reaches primary completion later than 18 of the 23 other live ones, and was the 43rd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

23 of the 46 studies in Pulmonary Disease, Chronic Obstructive by Assiut University are open now, in 1 country. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 23 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Pulmonary Disease, Chronic Obstructive by Assiut University, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate if standard, easily accessible blood tests can help doctors predict the severity and outcomes of sudden flare-ups in patients with Chronic Obstructive Pulmonary Disease (COPD).

When a patient's COPD suddenly worsens, an event called an acute exacerbation, it can lead to serious health complications, breathing difficulties, and hospitalization. Currently, doctors need simple and cost-effective ways to figure out early on which patients are at the highest risk for severe complications.

This observational study will focus on specific components of a routine Complete Blood Count (CBC) test. Researchers will look at the size, volume, and variation of red blood cells (such as Red Cell Distribution Width, or RDW) and platelets. Both red blood cells and platelets are known to be affected by the body's systemic inflammatory response during a severe COPD flare-up.

Participants will include adults over 18 years old who are admitted to the hospital for an acute exacerbation of COPD. As part of the study, researchers will collect and analyze routine clinical data, including:

  • Medical history and physical examination findings (including dyspnea severity).
  • Standard laboratory blood tests (evaluating red blood cells, platelets, kidney and liver function, and inflammation markers).
  • Arterial blood gas levels.
  • Pulmonary function tests (breathing tests to measure lung capacity).
  • High-resolution computed tomography (HRCT) chest scans.

By analyzing this information, the study aims to determine if red blood cell and platelet indices can accurately predict important clinical outcomes. These outcomes include the need for Intensive Care Unit (ICU) admission, the need for a mechanical ventilator (breathing machine), the total length of the hospital stay, and in-hospital mortality. Identifying reliable biomarkers could help healthcare providers make faster, more targeted treatment decisions for COPD patients.

Read the detailed description

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disorder characterized by persistent airflow limitation and a heightened inflammatory response in the airways. While traditionally viewed strictly as a pulmonary condition, COPD is now widely understood to encompass systemic inflammation, oxidative stress, and immune dysregulation. The clinical trajectory of COPD is frequently punctuated by acute exacerbations (AECOPD), defined as a sudden and severe worsening of respiratory symptoms. These exacerbations accelerate lung function decline, increase the risk of acute respiratory failure (ARF), and are associated with recurrent hospitalizations and high mortality rates.

During an AECOPD, patients experience high-grade systemic inflammation, which is typically reflected by elevated conventional markers such as C-reactive protein (CRP). However, there is a pressing clinical need for more accessible, rapid, and cost-effective biomarkers to aid in early risk stratification upon hospital admission.

Routine hematological analysis, specifically the complete blood count (CBC), offers several promising, non-invasive prognostic markers.

Red Cell Distribution Width (RDW) is a quantitative measure of anisocytosis (variability in red blood cell size). Evidence indicates that elevated RDW is not just a marker of anemia, but reflects underlying chronic inflammation, oxidative stress, and impaired erythropoiesis. In COPD, elevated RDW has been correlated with disease severity, hypercapnia, prolonged hospital stays, and increased risk of in-hospital and ICU mortality.

Furthermore, platelets are critical mediators in inflammatory processes and endothelial dysfunction. Platelet activation plays a role in the pathophysiology of COPD exacerbations. Inflammatory cytokines can interfere with megakaryopoiesis, altering platelet production and activation dynamics. Consequently, indices such as Mean Platelet Volume (MPV), Platelet Distribution Width (PDW), Plateletcrit (PCT%), and the Platelet Large Cell Ratio (P-LCR) undergo significant changes during an acute exacerbation.

Despite this evidence, the combined clinical utility of RDW and specific platelet indices in predicting distinct severity grades and clinical outcomes in real-world AECOPD management remains incompletely defined.

This prospective cohort study aims to evaluate the combined prognostic utility of these basic hematological indices. Patients admitted to the Chest Diseases and Tuberculosis Department with a primary diagnosis of AECOPD will be evaluated.

Upon enrollment, all participants will undergo a comprehensive clinical assessment, including a detailed medical history and physical examination. Dyspnea severity will be clinically graded.

The diagnostic and assessment workflow includes:

  • Laboratory Investigations: A comprehensive metabolic and hematological panel will be drawn, focusing heavily on RBC indices (MCV, MCH, MCHC, RDW, Hct), Platelet Indices (PDW, PCT, MPV), and inflammatory ratios (Lymphocyte-to-Monocyte and Lymphocyte-to-Neutrophil ratios). Additional tests include kidney and liver function tests, coagulation profiles, ESR, and CRP.
  • Arterial Blood Gases (ABG): To assess respiratory failure status and gas exchange parameters (PaO2, PaCO2, SaO2, HCO3).
  • Pulmonary Function Tests (PFTs): To quantify airflow limitation (FEV1, FVC, and FEV1/FVC ratio) in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, as patient condition permits.
  • Radiological Assessment: High-Resolution Computed Tomography (HRCT) of the chest will be utilized as a non-invasive tool to characterize anatomical changes and identify further COPD phenotypes or complications.
03

Conditions studied

  • Acute Exacerbation of Chronic Obstructive Pulmonary Disease
  • Chronic Obstructive Pulmonary Disease (COPD)
  • AECOPD

Keywords

  • Red Blood Cell Indices
  • Platelet Indices
  • Red Cell Distribution Width (RDW)
  • Mean Platelet Volume (MPV)
  • Platelet Distribution Width (PDW)
  • Biomarkers
  • Prognosis
  • Systemic Inflammation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population consists of adult patients (over 18 years of age) diagnosed with Chronic Obstructive Pulmonary Disease (COPD) who are admitted to the Chest Diseases and Tuberculosis Department at Assiut University Hospital due to an acute exacerbation of their condition (AECOPD).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients above 18 years admitted to the department with AECOPD defined as an event characterized by increased dyspnea and/or cough and sputum that worsens in ≤14 days.

Exclusion criteria

Exclusion Criteria:

  • Primary reason for admission other than AECOPD.
  • The patient has a diagnosis of connective tissue disorder, inflammatory bowel disease, or hematological system diseases (such as , thalassemia, hemolytic anemia).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • AECOPD Patients

    Adult patients (over 18 years of age) admitted to the Chest Diseases and Tuberculosis department with an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD). Participants will undergo routine clinical and laboratory assessments, including complete blood counts to evaluate red blood cell and platelet indices, arterial blood gases, pulmonary function tests (PFTs), and high-resolution computed tomography (HRCT) to predict disease severity and clinical outcomes.

06

What researchers measure

Primary outcomes

  1. Dyspnea Severity Score

    Dyspnea severity will be quantified using the modified Medical Research Council (mMRC) dyspnea scale. This scale evaluates the degree of breathlessness on a grading system from 0 to 4, with higher grades indicating more severe symptoms.

    Time frame: Baseline

Secondary outcomes

  1. Length of Hospital Stay

    The total number of days the patient remains hospitalized for the treatment of the acute exacerbation of COPD.

    Time frame: From the date of hospital admission until the date of hospital discharge, assessed up to 30 days.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 12 months is below that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2026
First posted
Jul 9, 2026
StartEst.
Aug 2026
Primary completionEst.
Aug 2027
CompletionEst.
Sep 2027
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07693127
Lead sponsor
Assiut University
Responsible party
Maha Elsayed Allam (Resident at Chest Diseases Department, Assiut University) — Principal investigator
First posted
Jul 9, 2026
Start date
Aug 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jul 9, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion